

- 60 -CLAIMS

- 1. (AMENDED) A cell comprising a vector containing a gene encoding a protein made of an amino acid sequence set forth in SEQ ID NO: 2 or amino acid sequence ranging from 394-position to 532-position in the amino acid sequence set forth in SEQ ID NO: 2, or a protein made of an amino acid sequence in SEQ ID NO: 4 or amino acid sequence ranging from 396-position to 534-postion of the amino acid sequence set forth in SEQ ID NO: 4, wherein a Toll-like receptor 3 is expressed in the cell.
- 2. (AMENDED) A cell as set forth in Claim 1, wherein the cell is a human fibroblast, a human dendritic cell, a human intestinal epithelial cell, or mouse fibroblast.
- 3. (AMENDED) A screening method for compound for inhibiting binding of Toll-like receptor 3 and the protein, the method comprising the steps of:

causing a candidate compound to be in contact with the cell as set forth in Claim 1 or 2; and

checking whether the protein and Toll-like receptor 3 bind to each other or not.

- 4. (AMENDED) A therapeutic agent for treating a disease that is able to be ameliorated by enhancing Type I interferon production, the therapeutic agent containing the cell as set forth in Claim 1 or 2.
- 5. (AMENDED) A therapeutic agent as set forth in Clai m 4, wherein the disease is cancer or a viral infectious disease.

٦

- 6. (AMENDED) A therapeutic agent as set forth in Claim 5, wherein the cancer is hepatoma, kidney cancer, juvenile pharynx villous tumor, malignant lymphoma, cerebral tumor, glioblastoma, medulloblastoma, astrocytoma, or dermal malignant melanoma.
- 7. (AMENDED) A therapeutic agent as set forth in Clai m 5, wherein the viral infectious disease is hepatitis B or h epatitis C.
- 8. (AMENDED) A therapeutic agent for treating a disease that is able to be ameliorated by enhancing Type I interferon production, the therapeutic agent containing a protein made of an amino acid sequence set forth in SEQ ID NO: 2 or amino acid sequence ranging from 394-position to 532-position in the amino acid sequence set forth in SEQ ID NO: 2, or a protein made of an amino acid sequence in SEQ ID NO: 4 or amino acid sequence ranging from 396-position to 534-postion of the amino acid sequence set forth in SEQ ID NO: 4, wherein a Toll-like receptor 3 is expressed in the cell.
- 9. (AMENDED) A therapeutic agent for treating a disease that is able to be ameliorated by enhancing Type I interferon production, the therapeutic agent containing a vector containing a gene encoding a protein made of an amino acid sequence set forth in SEQ ID NO: 2 or amino acid sequence ranging from 394-position to 532-position in the amino acid sequence set forth in SEQ ID NO: 2, or a protein made of an amino acid sequence in SEQ ID NO: 4 or amino acid sequence ranging from 396-position to 534-postion of the amino acid sequence set forth in SEQ ID NO: 4, wherein a Toll-like receptor



3

3 is expressed in the cell.

10. (AMENDED) A therapeutic agent for treating a disease that is able to be ameliorated by enhancing Type I interferon production, the therapeutic agent containing a cell containing a vector containing a gene encoding a protein made of an amino acid sequence set forth in SEQ ID NO: 2 or amino acid sequence ranging from 394-position to 532-position in the amino acid sequence set forth in SEQ ID NO: 2, or a protein made of an amino acid sequence in SEQ ID NO: 4 or amino acid sequence ranging from 396-position to 534-postion of the amino acid sequence set forth in SEQ ID NO: 4, wherein a Toll-like receptor 3 is expressed in the cell.

- 11. (CANCELLED)
- 12. (CANCELLED)
- 13. (CANCELLED)
- 14. (CANCELLED)
- 15. (CANCELLED)
- 16. (CANCELLED)
- 17. (CANCELLED)
- 18. (CANCELLED)
- 19. (CANCELLED)
- 20. (CANCELLED)
- 21. (CANCELLED)
- 22. (CANCELLED)